The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a twice-yearly injectable drug developed for adults and teenagers.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries?

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.